Home Tags Lung Disease
Lung Disease Related Content
Michael Roth discusses soluble circulating cytokine receptors in chronic inflammatory lung diseases, which he describes as the under-estimated regulators of inflammation and remodelling.
Stephen C Clark, from Newcastle upon Tyne Hospitals NHS Foundation Trust and University of Northumbria in the UK explains idiopathic pulmonary fibrosis, a type of lung disease.
Michael Roth, Research Group Leader at University Hospital Basel asks if fine dust air pollution (PM2.5) is a cause of chronic inflammatory lung diseases and provides a most engaging response.
Daikin reviews whether air pollution in the UK has improved over the years and details how chemical compounds and matter existing in our air pose a threat to our planet.
More can be done at the local, national and EU level to improve COPD diagnosis, support smoking cessation and advance work and living conditions for people living with COPD.
NHS England has announced it has secured a definitive cystic fibrosis drugs agreement with Vertex Pharmaceuticals, to use all three of their UK-licensed medicines.
Steve Jones, Chair Action for Pulmonary Fibrosis and Board Member EU-IPFF and Gisli Jenkins from Nottingham University Hospitals, explain idiopathic pulmonary fibrosis (IPF), an incurable lung disease.
Karen Moor and Marlies Wijsenbeek from the Erasmus Medical Center, Rotterdam explore the role of eHealth tools in idiopathic pulmonary fibrosis care and research.
Michael Roth, Research Group Leader at University Hospital Basel asks if disturbed cell-cell interaction causes asthma and provides a fascinating response.
The restriction or inhalation of common sugar could one day treat a range of respiratory diseases, according to new research led by University of Manchester biologists.
The University of Manchester found that patients with common lung diseases are substantially more likely to suffer a heart attack and develop other major heart problems.
New figures show nearly 18 million patients are exposed to pollution, registered at GP surgeries with unsafe levels in the UK: read on to find out who is affected by these findings
Michael Roth, Research Group Leader at the University Hospital Basel explains what asthma is, its health impact and charts research landscape in the field.
Michael Roth, Research Group Leader at the University Hospital Basel & University Basel share his expertise on asthma and COPD, the most prevalent chronic inflammatory diseases of the lung globally
An innovative new surgery could provide a breakthrough in treating early-stage lung cancer, based on a review of some of the first patients to receive the treatment.
Prof Dr Michael Roth asks the question, Why do we fail to find disease specific indicators for chronic inflammatory lung diseases?
Michael Roth, Research Group Leader at University Hospital Basel argues for the clear need to improve the diagnosis of chronic inflammatory lung diseases
Michael Roth, Research group leader at the University & University Hospital Basel explores the current state of chronic inflammatory lung diseases, from the molecular biology perspective
Associate Professor of Medicine, Anesthesiology and Critical Care at Université Clermont Auvergne, Matthieu Jabaudon assesses the RAGE pathway in at-risk critically ill patients and asks if this is a step towards better acute respiratory distress syndrome (ARDS) prediction
Cecilia Van Cauwenberghe, from TechVision Group, Frost & Sullivan provides a fascinating overview of acute respiratory distress syndrome, including refocusing clinical concerns and disease management, as well as the overall characteristics and health implications
12Page 1 of 2